Changing from preserved, to preservative-free cyclosporine 0.1% enhanced triple glaucoma therapy: impact on ocular surface disease – a randomized controlled trial

Konstas A.-G., Boboridis K. G., Athanasopoulos G. P., Haidich A.-B., Voudouragkaki I. C., Pagkalidou E., Katsanos A., Katz L. J.

2023
Eye

View publication

Therapeutic Area

Glaucoma
Categories

Clinical development

Affiliations

University Department of Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki, Greece; Department of Epidemiology, Aristotle University of Thessaloniki, Thessaloniki, Greece; Department of Ophthalmology, University of Ioannina, Ioannina, Greec; Glaucoma Research Center, Wills Eye Hospital, Philadelphia, PA, USA

Related Publications

Associations between Clustered Visual Field Progression and Locations of Disc Hemorrhages in Glaucoma: A Three-year Prospective Study

Akagi T.; Fukuchi T.; Higashide T.; Udagawa S.; Ohkubo S.; Sugiyama K.; Tanihara H.; Araie M.; Tomita G.; Matsumoto C.; Tomidokoro A.; Hangai M.; Kawata H.; Inai M.; Tanaka Y.; SVF Prospector Study Group

Proteome-Wide Analysis of Autoantibodies in Open-Angle Glaucoma in Japanese Population: A Pilot Study

Takada N.; Ishikawa M.; Sato K.; Kunikata H.; Ninomiya T.; Hanyuda A.; Fukuda E.; Yamaguchi K.; Ono C.; Kirihara T.; Shintani C.; Tsusu C.; Osanai A.; Goshima N.; Izumi Y.; Zorumski C.F.; Nakazawa T.

Bioequivalence of Preservative-free and Preserved Omidenepag Isopropyl (OMDI) 0.002% Ophthalmic Solutions in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: Results from the Phase 3 DAISY Study

Aihara M.; Lu F.; Ikeda T.; Odani-Kawabata N.

View all Glaucoma publications